CXCR4-targeted molecular imaging has been extensively evaluated across different hematologic and solid neoplasms, and the results indicate that 68Ga-pentixafor may emerge as a novel pan-hematologic tumor agent. Here, CXCR4 is linked to hematopoietic and lymphoid cell neoplasm.